Watson Pharmaceuticals gets the OK from FDA for new nicotine polacriliex gum
MORRISTOWN, N.J. Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals, announced its subsidiary, Watson Labs, has been granted approval from the Food and Drug Administration to market its nicotine polacrilex gum.
Nicotine polacrilex gum is the generic equivalent of GlaxoSmithKline Consumer Healthcare’s Nicorette Fruit Chill and Cinnamon Surge Coated gums, all of which are available over-the-counter and used to help people stop smoking.
Watson’s nicotine gum will be available as soon as possible in coated fruit and cinnamon flavors.
Bartell Drugs collects food for people in need
SEATTLE A regional retail pharmacy chain has collected enough food for more than 15,000 meals for people in need.
Bartell Drugs announced Thursday that its “Stock the Pantry” food drive, which it had conducted with Northwest Harvest and Fisher Communications, had collected 16,767 pounds of food through the chain’s 55 stores in King, Pierce and Snohomish counties.
“Year-around hunger is an unfortunate reality for many children and their families, as well as many seniors,” Bartell chairman and CEO George Bartell said. “Through the generous contributions by our customers, we’re proud to support Northwest Harvest with this effort.
The food drive was launched in May as a way to help Northwest Harvest replenish its food stocks during the summer months.
OSI Pharmaceuticals moving to Westchester Co., N.Y.
MELVILLE, N.Y. Biotech company OSI Pharmaceuticals plans to move its U.S. operations to a single campus in upstate New York, the company announced this week.
OSI announced that it had purchased a 43-acre site in Ardsley, a community in the town of Greenburgh, N.Y., and would move 350 employees from Melville and Farmingdale, N.Y., Cedar Knolls, N.J., and Boulder, Colo., to the new campus in the second half of this year.
“The past 10 years has been a remarkable journey as the company has successfully brought its first oncology product, Tarceva, to market and taken the business profitable,” OSI CEO Colin Goddard said. “Nonetheless, we have recognized that we will only truly capture the full strategic value of our oncology franchise if we simplify our business by bringing together all the elements of our U.S. operations onto a single site.”